Section 17D.
(a)The commissioner shall report quarterly to the house and senate committees on ways and means, the joint committee on mental health, substance use and recovery, the joint committee on public safety and homeland security and the joint committee on the judiciary the following information for the prior calendar year for each facility included in section 17B:
(i)the cost to the facility of providing medication-assisted treatment for opioid use disorder;
(ii)the cost to the facility of providing re-entry treatment plans under section 17C;
(iii)the type and prevalence of medication-assisted treatment provided for opioid use disorder;
(iv)the number of persons in the custody of the facility, in any status, who continued to receive the same medication-assisted treatment as they
Free access — add to your briefcase to read the full text and ask questions with AI
Section 17D. (a) The commissioner shall report quarterly to the house and senate committees on ways and means, the joint committee on mental health, substance use and recovery, the joint committee on public safety and homeland security and the joint committee on the judiciary the following information for the prior calendar year for each facility included in section 17B: (i) the cost to the facility of providing medication-assisted treatment for opioid use disorder; (ii) the cost to the facility of providing re-entry treatment plans under section 17C; (iii) the type and prevalence of medication-assisted treatment provided for opioid use disorder; (iv) the number of persons in the custody of the facility, in any status, who continued to receive the same medication-assisted treatment as they received prior to incarceration, by medication type; (v) the number of persons in the custody of the facility, in any status, who changed or discontinued medication-assisted treatment for opioid use disorder that they received prior to incarceration, by medication type; (vi) the number of persons in the custody of the facility, in any status, who received medication-assisted treatment for opioid use disorder during the 90 days prior to release, by medication type; (vii) the number of persons in the custody of a facility, in any status, with a re-entry treatment plan that included medication-assisted treatment but did not receive such treatment prior to release; (viii) the number of persons in the custody of the facility, in any status, who received medication-assisted treatment for opioid use disorder who did not receive such treatment prior to incarceration, by medication type; (ix) a summary of facility practices and any changes to those practices related to medication-assisted treatment for opioid use disorder; (x) the number of persons who were connected to treatment after release; (xi) the number of persons who received a re-entry treatment plan under section 17C and were subsequently enrolled in MassHealth upon discharge; provided, however, that the commissioner, the commissioner of medical assistance and the commissioner of public health shall coordinate to provide such information; and (xii) any other information requested by the commissioner related to the provision of medication-assisted treatment for opioid use disorder.Every 2 years, not later than the April 30, the commissioner of public health shall prepare a report, pursuant to section 237 of chapter 111, regarding outcomes for the medication-assisted treatment programs established under sections 17B and 17C to the house and senate committees on ways and means, the joint committee on mental health, substance use and recovery, the joint committee on public safety and homeland security and the joint committee on the judiciary. The department of correction shall provide, upon request from the commissioner of public health, information necessary to prepare the report. The report shall, to the extent possible, provide a comparison between the state detainees and prisoners who did not receive medication-assisted treatment for opioid use disorder and those who did, reported separately for each medication type, in order to determine the impact of the treatment programs on the following: (i) retention in treatment after release; (ii) substance use and relapse after release; (iii) rates of recidivism; (iv) rates of nonfatal and fatal overdose; (v) treatment retention after release; and (vi) other outcome measures identified by the commissioner of public health.